
O-1449 U.S. Department of Commerce Attorney Docket Number Serial No. Patent and Trademark Office 5470.378 10/672,501 LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary) Applicants: Kole Filing Date: September 26, 2003 Group 1645 **U. S. PATENT DOCUMENTS** Examiner **Document** Filing Date Initial Number Date Name Class Subclass if Appropriate FOREIGN PATENT DOCUMENTS **Document** Translation Number Date Country Class Subclass Yes | No WO 01/79853 October 25, 2001 **PCT** 1. WO 00/67580 November 16, 2000 **PCT** 2. OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) International Search Report corresponding to PCT/US03/30423, filed May 28, 2004

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office					Attorney Docket Number 5470.378		Serial No. 10/672,501		
LIST OF DOCUMENTS CITED BY APPLICANT									
OFE COUSE several sheets if necessary)						Applicants: Kole			
(100 H							<u> </u>		
WIN O S TOOK SEE				Filing Date: September 26, 2003			Group		
C TENTATE	- CALE						<u></u>		1645
WATE	ADE			U. S. PATE	NT DOCU	JMENTS		····	
Examiner		Document		_					Filing Date
Initial		Number	Date			Name	Class	Subclass	if Appropriate
NO.	1.	5,023,243	06	7/11/91	Tullis				прргорише
03.7		5,149,797	ng	/22/92	Pederso	n et al		_	
I N	2.								
N/A	3.	5,220,007	06	/15/93	Pederso	n et al.			•
	٠								
			F(OREIGN PA	TENT DO	CUMENTS			
		Document							Translation
		Number	}	Date		Country	Class	Subclass	Yes No
			•			•			1
		OTHER DOCUM	ENT	rs (Including	Author 7	itle Date Pertin	ent Pages F	tc)	
9994	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) 4. "Antisense Used to Correct Genetic Defect" Nature Biotechnology 14:1637 (1996)								
	5.	Baudys et al. "Stabilization and Intestinal Absorption of Human Calcitonin" Journal of Controlled Release 39:145-151 (1996)							
	6.	Bennett "Antisense Research" Science 271:434 (1996)							
	7.	Bennett et al. "Cationic Lipids Enhance Cellular Uptake and Activity of Phosphorothioate Antisense							
	,.		Oligonucleotides" Molecular Pharmacology 41(6):1023-1033 (1992)						
	8.	DeLong et al. "Novel Cationic Amphiphiles as Delivery Agents for Antisense Oligonucleotides" <i>Nucleic Acids Research</i> 27(16):3334-3341 (1999)							
	9.	Dobkin and Bank "Reversibility of IVS 2 Missplicing in a Mutant Human \(\mathcal{B}\$-Globin Gene" The Journal of							
		Biological Chemistr						0: 01 :	
	10.	Dominski and Kole and Cellular Biolog				A Sequence Elem	ients in Splic	e Site Selecti	on" <i>Molecular</i>
	11.	Dominski and Kole	"Ide	ntification a	nd Charact				
2727		Sequences Required							
IY/H	12.	Dominski and Kole Biological Chemistr					in Splice Sil	ie Selection".	Journal of
9794	13.	Dominski and Kole	"Re	storation of (Correct Sp	licing in Thalasse	emic Pre-MR	NA by Antis	ense
0.00		Oligonucleotides" P					th Chart Into	mal Evanal' i	Malassian and
1/14	14.	Dominski and Kole "Selection of Splice Sites in Pre-mRNAs with Short Internal Exons" <i>Molecular and Cellular Biology</i> 11(12):6075-6083 (1991)							
9,21	Friedman et al. "Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance								
M		Regulator (CFTR) Gene by Antisense Oligonucleotides" Journal of Biological Chemistry 274(51):36193-							

EXAMINER *EXAMINER



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office			Attorney Docket Number 5470.378	Serial No. 10/672,501			
LIST C	F DOC	CUMENTS CITED BY APPLICANT					
OIP E C	(Use	several sheets if necessary)					
Ann.	<u> </u>		Applicants: Kole				
MAY 0 5 2004	. EE		Filing Date: September 26, 2003	Group			
1 -A 1 65	Y			1645			
7	16.	Furdon and Kole "Inhibition of in Vitro pre-mR <u>Journal of Cellular Biochemistry</u> Suppl. 130:#K		otide Analogues"			
	17.	Furdon and Kole "The Length of the Downstream Exon and the Substitution of Specific Sequences Affect Pre-mRNA Splicing In Vitro" Molecular and Cellular Biology 8(2): 860-866 (1988)					
	18.	Furdon et al. "RNase H Cleavage of RNA Hybridized to Oligonucleotides Containing Methylphosphonate, Phosphorothioate and Phosphodiester Bonds" Nucleic Acids Research 17(22):9192-9204 (1989)					
	19.	Gorman et al. "Restoration of Correct Splicing of Thalassemic B-Globin Pre-mRNA by Modified U1 snRNAs" Journal of Biological Chemistry 275(46):35914-35919 (2000)					
	20.	Gorman et al. "Stable Alteration of Pre-MRNA Splicing Patterns by Modified U7 Small Nuclear RNAs" Proc. Natl. Acad. Sci. USA 95:4929-4934 (1998)					
	21.	Gura "Antisense Has Growing Pains" Science 270:575-577 (1995)					
	22.	Kole and Weissman "Accurate In Vitro Splicing of Human β-Globin RNA" Nucleic Acids Research 10(18):5429-5445 (1982)					
	23.	Kole et al. "Pre-mRNA Splicing as a Target for Antisense Oligonucleotides" Advanced Drug Delivery					
	24.	Reviews 6:271-286 (1991) Kulka et al. "Site Specificity of the Inhibitory Effects of Oligo (nucleoside Methylphosphonate)s Complementary to the Acceptor Splice Junction of Herpes Simplex Virus Type 1 Immediate Early mRNA					
	25.	4" Proc. Natl. Acad. Sci. USA 86:6868-6872 (1989) Lacerra et al. "Restoration of Hemoglobin A Synthesis in Erythroid Cells from Peripheral Blood of					
	26.	Thalassemic Patients" PNAS 97(17):9591-9596 (2000) Lewis et al. "A Common Human & Globin Splicing Mutation Modeled in Mice" Blood 91(6):2152-2156 (1998)					
PMA	27.	Mercatante et al. "Modification of Alternative Splicing of Bcl-x Pre-mRNA in Prostrate and Breast Cancer Cells" <i>Journal of Biological Chemistry</i> 276(19):16411-16417 (2001)					
RIA	28.	Miller et al. "Gene Transfer and Antisense Nucle (1994)		0(3):92-97			
9794	29.	Milligan et al. "Current Concepts in Antisense Drug Design" J. Medicinal Chemistry 36(14):1923-1937 (1993)					
	30.	Munroe "Antisense RNA Inhibits Spicing of Pre-MRNA In Vitro" The EMBO Journal 7(8):2523-2532 (1988)					
	31.	Rapaport et al. "Antimalarial Activities of Oligodeoxynucleotide Phosphorothioates in Chloroquine-Resistant Plasmodium falciparum" Proc. Natl. Acad. Sci. USA 89:8577-8580 (1992)					
	32.	Reed and Maniatis "Intron Sequences Involved in Lariat Formation during Pre-mRNA Splicing" Cell 41:95-101 (1985)					
	33.	Rojanasakul "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting" Advanced Drug Delivery Reviews 18:115-131 (1996)					
	34.	Ruskin and Green "Specific and Stable Intron-Factor Interactions are Established Early During in Vitro Pre- mRNA Splicing" Cell 43:131-142 (1985)					
	35.	Ryder et al. "Sequence-Specific Affinity Selection of Mammalian Splicing Complexes" Nuc. Acids. Res. 18(24):7373-7374 (1990)					
M	36.	Sazani and Kole "Therapeutic Potential of Antis Splicing" Journal of Clinical Investigation 112(4	ense Oligonucleotides as Modulators of Alt 4):481-486 (2003)	ernative			

EXAMINER *EXAMINER

HURLICK

DATE CONSIDERED 12/19/05

	U.S. Department of Commerce at and Trademark Office	Attorney Docket Number 5470.378	Serial No. 10/672,501				
IPE A	CUMENTS CITED BY APPLICANT e several sheets if necessary)		_				
MAY 0 5 20TH THE		Applicants: Kole					
A SET		Filing Date: September 26, 2003	Group 1645				
37.	Schmajuk et al. "Antisense Oligonucleotides wii 274(31):21783-21789 (1999)		ical Chemistry				
38.	Sierakowska et al. "Antibodies to hnRNP Core Proteins Inhibit In Vitro Splicing of Human B-Globin Pre- mRNA" Nucleic Acids Research 14(3):5241-5254 (1986)						
39.	Sierakowska et al. "Inhibition of Pre-mRNA Splicing by 5-Fluoro-, 5-Chloro-, and 5-Bromouridine" Journal of Biological Chemistry 264(32):19185-19191 (1989)						
40.	Sierakowska et al. "Repair of Thalassemic Human B-Globin mRNA in Mammalian Cells by Antisense Oligonucleotides" <i>Proc. Natl. Acad. Sci. USA</i> 93:12840-12844 (1996)						
41.	Stein "Does Antisense Exist?" Nature Medicine 1:1119-1121 (1995)						
42.	Stein and Cheng "Antisense Oligonucleotides as Therapeutic Agents – Is the Bullet Really Magical?" Science 261:1001-1012 (1993)						
43.	Stull et al. "Antigene Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects" <i>Pharmaceutical Research</i> 12(4):465-483 (1995)						
929 44.	Suter et al. "Double-Target Antisense U7 snRNAs Promote Efficient Skipping of an Aberrant Exon in Three Human B-Thalassemic Mutations" Human Molecular Genetics 8(13):2415-2423 (1999)						
45.	Tian et al. "Selection of Novel Exon Recognition Elements from a Pool of Random Sequences" Molecular and Cellular Biology 15(11):6291-6298 (1995)						
46.	Tseng et al. "Antisense Oligonucleotide Technology in the Development of Cancer Therapeutics" Cancer Gene Ther. 1:65-71 (1994)						
Y 47.	Uhlmann et al. "Antisense Oligonucleotides: A New Therapeutic Principle" Chem. Rev. 90:544-579 (1990)						
48.	Volloch et al. "Inhibition of Pre-mRNA Splicing by Antisense RRNA in Vitro: Effect of RNA Containing Sequences Complementary to Exons" <i>Biochemical and Biophysical Research Communications</i> 179(3):1593-1599 (1991)						
RM 49.	Wagner "Gene Inhibition Using Antisense Oligodeoxynucleotides" Nature 372:333-335 (1994)						
50.	Wagner "The State of the Art in Antisense Rese	arch" Nature Medicine 1:1116-1118 (1995)				
51.	Weiss "Upping the Antisense Ante" Science New	ws 139:108-109 (1991)					
52.	Westerman et al. "Inhibition of Expression of SV40 Virus Large T-Antigen by Antisense Oligodeoxyribonucleotides" Biomed. Biochim. Acta. 48:85-93 (1989)						
53.	Wu-Pong "Oligonucleotides: Opportunities for Drug Therapy Research" Pharmaceutical Technology 18:102-114 (1994)						
PH 54.	Zhuang and Weiner "A Compensatory Base Change in Human U2 snRNA Can Suppress a Branch Site Mutation" Genes & Development 3(10):1545-1552 (1989)						

EXAMINER *EXAMINER